CME: Improving the Quality of Care for Patients Harboring ALK+ NSCLC - Global Oncology Academy

Improving the Quality of Care for Patients Harboring ALK+ NSCLC

Improving the Quality of Care for Patients Harboring ALK+ NSCLC

3

Guest: D. Ross Camidge, MD, PhD

3

Overview
The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.)
Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on the management of ALK+ metastatic NSCLC, making it challenging to provide state-of-the-art care to their patients.
This activity will review molecular testing for ALK rearrangements, approved and emerging therapeutic options for the first-line treatment of ALK+ NSCLC and treatment upon disease progression, treatment selection and sequencing, and efficacy and safety data of ALK inhibitors.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
1. Perform molecular biomarker testing in patients with advanced NSCLC according to guideline recommendations
2. Select optimal first-line therapy for advanced ALK+ NSCLC based on patient and disease-related factors, and systemic and intracranial efficacy data, and safety
3. Examine mechanisms of acquired resistance in ALK+ NSCLC and the impact on treatment decision-making and sequencing strategies
4. Develop treatment plans for patients with advanced ALK+ NSCLC that include individual patient preferences while addressing symptoms, needs, and quality of life
Target Audience
This activity is intended for thoracic oncologists, medical oncologists, pulmonologists, pathologists, histologists, physician assistants, nurse practitioners, pharmacists, risk managers, and other healthcare professionals who treat or manage patients with ALK+ NSCLC.
Faculty Disclosure
Disclosure of Conflict of Interest
AXIS Medical Education requires faculty, instructors, authors, planners, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. All identified conflicts of interest are thoroughly vetted and mitigated by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and mitigate all conflicts of interestthat faculty and authors disclose prior to an educational activity being delivered/presented to learners. AXIS will identify, review, and mitigate all conflicts of interestthat activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to initiation of the planning phase for an educational activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided for this activity.
The faculty reported the following financial relationships or relationships they have with ineligible company of any amount during the past 24 months. D. Ross Camidge, MD, PhD, reported a financial interest/relationship or affiliation in the form of Advisor: Amgen, Inc; 14ner Oncology; AbbVie; Achilles Therapeutics; Anchiano Therapeutics; Apollomics, Inc; Archer Pharmaceuticals; Arrys/Kyn; AstraZeneca Pharmaceuticals LP; BeyondSpring, Inc; Blueprint Medicines; Bristol-Myers Squibb Co; Daiichi-Sankyo, Inc; Elevation; Eli Lilly and Co; EMD Serono, Inc; GlaxoSmithKline; Hansoh Pharmaceuticals; Helsinn Therapeutics (US) Inc; Hengrui Therapeutics; Inviata; Janssen Oncology; Medtronic Inc; OnKure Therapeutics; Pfizer, Inc; Qilu Pharmaceuticals; Regeneron Pharmaceuticals, Inc; Ribon Therapeutics; Roche; Sanofi; Seattle Genetics, Inc; and Takeda Oncology. Clinical trial support: AbbVie; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Co; GlaxoSmithKline; Hansoh Pharmaceuticals; InhibRx; Karyopharm Therapeutics, Inc; Lycera; MedImmune; Merck & Co, Inc; Pfizer, Inc; Phosplatin Therapeutics; PsiOxus Therapeutics; Rain Therapeutics; Roche/Genentech; Seattle Genetics, Inc; Symphogen; Takeda Oncology; and Tolero Pharmaceuticals. Data and safety monitoring board: Biothera and G1 Therapeutics.
The planners, directors, managers, peer reviewers, and relevant staff Linda Gracie-King, MS; Jocelyn Timko, BS; Joseph Kim, MPH, MBA, MD; Marilyn L. Haas-Haseman, RN, CNS, PhD, ANP-BC; and Adrienne N. Nedved, PharmD., MPA., BCOP hereby state that they do not have any financial relationships or relationships to products or devices with any ineligible company of any amount during the past 24 months.
Accreditation and Credit Designation Statements
ACCREDITED CONTINUING EDUCATION
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Q Synthesis LLC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 6/13/2021. PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-9999-21-067-H01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Provider(s)/Educational Partner(s)
Jointly Provided by
Commercial Support
Supported by an educational grant from Genentech, a member of the Roche Group.
Terms of Use
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
Disclaimer
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation and Request for Credit:
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.
There is no fee for this educational activity.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Recommended

- Amrita Krishnan, MD
  Peer
- Morie Gertz, MD, MACP
  Peer
2
CME/CE
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma
0.25 credits
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Rel…
0.25 credits
- Cesar Rodriquez Valdes, MD
  Peer
- Amrita Krishnan, MD
  Peer
3
CME/CE
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
0.25 credits
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
0.25 credits
- Ian W. Flinn, MD, PhD
  Peer
- William Wierda, MD
  Peer
1
CME/CE
Tackling Adverse Events Associated with Disruption of B-Cell Receptor Signaling: A Multispecialty Approach
Tackling Adverse Events Associated with Disruption of B-Cell Receptor Signaling: A Multispecialty Approach
0.25 credits
Tackling Adverse Events Associated with Disruption of B-Cell Receptor Signaling…
0.25 credits
- Jacob D. Soumerai, MD
  Peer
- Andrew H. Lipsky, MD
  Peer
2
CME/CE
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
0.25 credits
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
0.25 credits

A Radiation Oncologist’s Perspective on COVID-19

A Radiation Oncologist’s Perspective on COVID-19

Learn More

A Radiation Oncologist’s Perspective on COVID-19

Guest
Gregory J Kubicek, MD

UP NEXT...

Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer

CME